A mammalian enhancer trap resource for discovering and manipulating neuronal cell types

  1. Yasuyuki Shima
  2. Ken Sugino
  3. Chris Martin Hempel
  4. Masami Shima
  5. Praveen Taneja
  6. James B Bullis
  7. Sonam Mehta
  8. Carlos Lois
  9. Sacha B Nelson  Is a corresponding author
  1. Brandeis University, United States
  2. Janelia Research Campus, Howard Hughes Medical Institute, United States
  3. Galenea Corporation, United States
  4. California Institute of Technology, United States

Abstract

There is a continuing need for driver strains to enable cell type-specific manipulation in the nervous system. Each cell type expresses a unique set of genes, and recapitulating expression of marker genes by BAC transgenesis or knock-in has generated useful transgenic mouse lines. However since genes are often expressed in many cell types, many of these lines have relatively broad expression patterns. We report an alternative transgenic approach capturing distal enhancers for more focused expression. We identified an enhancer trap probe often producing restricted reporter expression and developed efficient enhancer trap screening with the PiggyBac transposon. We established more than 200 lines and found many lines that label small subsets of neurons in brain substructures, including known and novel cell types. Images and other information about each line are available online (enhancertrap.bio.brandeis.edu).

Article and author information

Author details

  1. Yasuyuki Shima

    Department of Biology and Center for Behavioral Genomics, Brandeis University, Waltham, United States
    Competing interests
    No competing interests declared.
  2. Ken Sugino

    Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States
    Competing interests
    No competing interests declared.
  3. Chris Martin Hempel

    Galenea Corporation, Wakefield, United States
    Competing interests
    No competing interests declared.
  4. Masami Shima

    Department of Biology and National Center for Behavioral Genomics, Brandeis University, Waltham, United States
    Competing interests
    No competing interests declared.
  5. Praveen Taneja

    Department of Biology and National Center for Behavioral Genomics, Brandeis University, Waltham, United States
    Competing interests
    No competing interests declared.
  6. James B Bullis

    Department of Biology and National Center for Behavioral Genomics, Brandeis University, Waltham, United States
    Competing interests
    No competing interests declared.
  7. Sonam Mehta

    Department of Biology and National Center for Behavioral Genomics, Brandeis University, Waltham, United States
    Competing interests
    No competing interests declared.
  8. Carlos Lois

    Division of Biology and Biological Engineering Beckman Institute, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
  9. Sacha B Nelson

    Department of Biology and National Center for Behavioral Genomics, Brandeis University, Waltham, United States
    For correspondence
    nelson@brandeis.edu
    Competing interests
    Sacha B Nelson, Reviewing editor, eLife.

Reviewing Editor

  1. Liqun Luo, Howard Hughes Medical Institute, Stanford University, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#14004) of Brandeis University. All surgery was performed under ketamine and xylazine anesthesia, and every effort was made to minimize suffering.

Version history

  1. Received: December 3, 2015
  2. Accepted: March 18, 2016
  3. Accepted Manuscript published: March 21, 2016 (version 1)
  4. Accepted Manuscript updated: April 6, 2016 (version 2)
  5. Version of Record published: April 21, 2016 (version 3)

Copyright

© 2016, Shima et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,269
    Page views
  • 1,161
    Downloads
  • 39
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yasuyuki Shima
  2. Ken Sugino
  3. Chris Martin Hempel
  4. Masami Shima
  5. Praveen Taneja
  6. James B Bullis
  7. Sonam Mehta
  8. Carlos Lois
  9. Sacha B Nelson
(2016)
A mammalian enhancer trap resource for discovering and manipulating neuronal cell types
eLife 5:e13503.
https://doi.org/10.7554/eLife.13503

Share this article

https://doi.org/10.7554/eLife.13503

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.